New Triple-Threat attack on lung cancer before surgery
NCT ID NCT07318636
Summary
This early-stage study is testing a new combination treatment for patients with non-small cell lung cancer that can be removed by surgery. The goal is to see if adding a new cell therapy (NK010) to standard immunotherapy and chemotherapy before surgery is safe and might help shrink tumors. The study will enroll about 10 patients who have not had any prior cancer treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, 510000, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.